Zoetis (ZTS) Change in Accured Expenses (2014 - 2026)

Zoetis' (ZTS) quarterly Change in Accured Expenses came in at -$234.0 million in Q1 2026, down 13.59% year-on-year from -$270.8 million in Q1 2025, and down 365.91% on a QoQ basis from $88.0 million in Q4 2025.

Zoetis (ZTS) Change in Accured Expenses (2014 - 2026) Analysis & Trends

Zoetis (ZTS) has 13 years of Change in Accured Expenses data on file, last reported at -$234.0 million in Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 13.59% year-over-year to -$234.0 million in Q1 2026; TTM through Mar 2026 was $57.0 million, a 72.73% increase from a year earlier, with the FY2025 full-year figure at $85.0 million, down 25.44% from the prior year.
  • Change in Accured Expenses for Q1 2026 stood at -$234.0 million, down from $88.0 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for ZTS reached as high as $124.0 million in Q3 2024 and fell as low as -$234.0 million in Q1 2026.
  • Historically, Change in Accured Expenses has averaged -$8.7 million across 5 years, with a median of $32.0 million in 2023.
  • Across the five-year window, Change in Accured Expenses sank 208.33% in 2022 and soared 825.0% in 2024, its largest moves.
  • Year by year, Change in Accured Expenses stood at $47.0 million in 2022, then jumped by 100.0% to $94.0 million in 2023, then declined by 17.02% to $78.0 million in 2024, then grew by 12.82% to $88.0 million in 2025, then plunged by 365.91% to -$234.0 million in 2026.
  • Per Business Quant data, the three most recent Change in Accured Expenses figures were -$234.0 million in Q1 2026, $88.0 million in Q4 2025, and $101.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn -144.00 Mn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn -234.00 Mn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn -12.70 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn -14.30 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn -
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -234.00 Mn
Mar 31, 2026 -234.00 Mn
Dec 31, 2025 88.00 Mn
Dec 31, 2025 88.00 Mn
Sep 30, 2025 101.00 Mn
Sep 30, 2025 101.00 Mn
Jun 30, 2025 102.00 Mn
Jun 30, 2025 102.00 Mn
Mar 31, 2025 -206.00 Mn
Mar 31, 2025 -206.00 Mn
Dec 31, 2024 78.00 Mn
Dec 31, 2024 78.00 Mn
Sep 30, 2024 124.00 Mn
Sep 30, 2024 124.00 Mn
Jun 30, 2024 37.00 Mn
Jun 30, 2024 37.00 Mn
Mar 31, 2024 -125.00 Mn
Mar 31, 2024 -125.00 Mn
Dec 31, 2023 94.00 Mn
Dec 31, 2023 94.00 Mn